Literature DB >> 30585643

CR6-interacting factor 1 controls autoimmune arthritis by regulation of signal transducer and activator of transcription 3 pathway and T helper type 17 cells.

Jin-Sil Park1, Si-Young Choi1, Sun-Hee Hwang1, Sung-Min Kim1, JeongWon Choi1, Kyung-Ah Jung1, Ji Ye Kwon1, Young-Yun Kong2, Mi-La Cho1,3,4, Sung-Hwan Park1,5.   

Abstract

CR6-interacting factor 1 (CRIF1) is a nuclear protein that interacts with other nuclear factors and androgen receptors, and is implicated in the regulation of cell cycle progression and cell growth. In this study, we examined whether CRIF1 exerts an immunoregulatory effect by modulating the differentiation and function of pathogenic T cells. To this end, the role of CRIF1 in rheumatoid arthritis, a systemic autoimmune disease characterized by hyperplasia of synovial tissue and progressive destruction of articular cartilage structure by pathogenic immune cells [such as T helper type 17 (Th17) cells], was investigated. p3XFLAG-CMV-10-CRIF1 was administered to mice with collagen-induced arthritis 8 days after collagen type II immunization and the disease severity and histologic evaluation, and osteoclastogenesis were assessed. CRIF1 over-expression in mice with collagen-induced arthritis attenuated the clinical and histological signs of inflammatory arthritis. Furthermore, over-expression of CRIF1 in mice with arthritis significantly reduced the number of signal transducer and activator of transcription 3-mediated Th17 cells in the spleen as well as osteoclast differentiation from bone marrow cells. To investigate the impact of loss of CRIF1 in T cells, we generated a conditional CRIF1 gene ablation model using CD4-cre transgenic mice and examined the frequency of Th17 cells and regulatory T cells. Deficiency of CRIF1 in CD4+ cells promoted the production of interleukin-17 and reduced the frequency of regulatory T cells. These results suggest a role for CRIF1 in modulating the activities of Th17 cells and osteoclasts in rheumatoid arthritis.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  CR6-interacting factor 1; T helper type 17 cells; rheumatoid arthritis; signal transducer and activator of transcription 3; suppressor of cytokine signaling 3

Mesh:

Substances:

Year:  2019        PMID: 30585643      PMCID: PMC6418438          DOI: 10.1111/imm.13042

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

Review 1.  IL-17 and Th17 cells in human inflammatory diseases.

Authors:  Pierre Miossec
Journal:  Microbes Infect       Date:  2009-04-14       Impact factor: 2.700

2.  CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane.

Authors:  Soung Jung Kim; Min-chul Kwon; Min Jeong Ryu; Hyo Kyun Chung; Surendar Tadi; Yong Kyung Kim; Jin Man Kim; Sang Hee Lee; Ji Hoon Park; Gi Ryang Kweon; Seung-Wook Ryu; Young Suk Jo; Chul-Ho Lee; Hideyuki Hatakeyama; Yu-ichi Goto; Yong-Hyeon Yim; Jongkyeong Chung; Young-Yun Kong; Minho Shong
Journal:  Cell Metab       Date:  2012-07-19       Impact factor: 27.287

3.  Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.

Authors:  Mari A Nowell; Peter J Richards; Ceri A Fielding; Simona Ognjanovic; Nick Topley; Anwen S Williams; Gillian Bryant-Greenwood; Simon A Jones
Journal:  Arthritis Rheum       Date:  2006-07

4.  Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.

Authors:  M L Barnett; J M Kremer; E W St Clair; D O Clegg; D Furst; M Weisman; M J Fletcher; S Chasan-Taber; E Finger; A Morales; C H Le; D E Trentham
Journal:  Arthritis Rheum       Date:  1998-02

Review 5.  Rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Cell       Date:  1996-05-03       Impact factor: 41.582

6.  CR6-interacting factor 1 interacts with orphan nuclear receptor Nur77 and inhibits its transactivation.

Authors:  Ki Cheol Park; Kwang-Hoon Song; Hyo Kyun Chung; Ho Kim; Dong Wook Kim; Jung Hun Song; Eun Suk Hwang; Hye Sook Jung; Su-Hyeon Park; Insoo Bae; In Kyu Lee; Hueng-Sik Choi; Minho Shong
Journal:  Mol Endocrinol       Date:  2004-09-30

7.  IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner.

Authors:  Lai Wei; Arian Laurence; Kevin M Elias; John J O'Shea
Journal:  J Biol Chem       Date:  2007-09-20       Impact factor: 5.157

8.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

Authors:  Arian Laurence; Cristina M Tato; Todd S Davidson; Yuka Kanno; Zhi Chen; Zhengju Yao; Rebecca B Blank; Françoise Meylan; Richard Siegel; Lothar Hennighausen; Ethan M Shevach; John J O'shea
Journal:  Immunity       Date:  2007-03       Impact factor: 31.745

Review 9.  The role of interleukin-1 in bone resorption in rheumatoid arthritis.

Authors:  V Strand; A F Kavanaugh
Journal:  Rheumatology (Oxford)       Date:  2004-06       Impact factor: 7.580

Review 10.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

View more
  3 in total

1.  Association between the polymorphism of IL-17A and IL-17F gene with knee osteoarthritis risk: a meta-analysis based on case-control studies.

Authors:  Feifan Lu; Pei Liu; Qidong Zhang; Weiguo Wang; Wanshou Guo
Journal:  J Orthop Surg Res       Date:  2019-12-16       Impact factor: 2.359

Review 2.  Abnormal Expression of Mitochondrial Ribosomal Proteins and Their Encoding Genes with Cell Apoptosis and Diseases.

Authors:  Guomin Huang; Hongyan Li; Hong Zhang
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

Review 3.  Multifunctions of CRIF1 in cancers and mitochondrial dysfunction.

Authors:  Yangzhou Jiang; Yang Xiang; Chuanchuan Lin; Weiwei Zhang; Zhenxing Yang; Lixin Xiang; Yanni Xiao; Li Chen; Qian Ran; Zhongjun Li
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.